Efficacy of GSK Biologicals' candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in healthy adults living in a TB endemic region
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2017
At a glance
- Drugs GSK 692342 (Primary)
- Indications Tuberculosis
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 07 Jun 2017 Biomarkers information updated
- 15 Sep 2016 Planned End Date changed from 1 Nov 2018 to 1 Oct 2018.
- 15 Sep 2016 Planned primary completion date changed from 1 Nov 2018 to 1 Oct 2018.